ivonescimab
Coverage of ivonescimab in the Nexus archive.
- An experimental lung-cancer drug could replace Keytruda one day. But investors aren’t wowed.
An experimental lung-cancer drug, ivonescimab, showed a 34% reduction in risk of death compared to Keytruda. However, investors remain unimpressed by the results.
- Akeso lung cancer drug shines in trials, boosting hopes in US$20b market
Akeso's lung cancer drug ivonescimab showed better-than-expected clinical results for treating a type of lung cancer common in smokers. Analysts believe it could become a backbone therapy in the US$20 billion global non-small cell lung cancer market and raised target prices. Phase three trials found the drug reduced the risk of death.
- Akeso lung cancer drug shines in trials, boosting hopes in US$20b market
Akeso's drug ivonescimab showed better-than-expected clinical results for treating a type of lung cancer common in smokers, potentially expanding its approved uses. Analysts predict it could become a backbone therapy in the US$20 billion global non-small cell lung cancer market, with revised upward target prices.
- STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
Ivonescimab, developed by Akeso Therapeutics and Summit Therapeutics, reduced the risk of death by 34% in patients with squamous non-small cell lung cancer compared to standard treatment in a China-based clinical trial. Results were presented at the American Society of Clinical Oncology meeting and published in The Lancet, with Summit’s co-CEO highlighting the drug’s potential business value.